AR mutations remain infrequent among treatment naïve prostate cancer patients but are detected in almost 20% of those with castration resistant disease, and in up to 40% of patients who have received ARTA.(12) There did not appear to be a unique genomic landscape among patients who develop AR alterations at castration resistance without prior ARTA compared to those who develop AR alterations after exposure to ARTA. This evidence concerns the gene AR and prostate carcinoma.